United States Drug Patent 10,675,287: Claim Scope, Validity Risks, Orange Book Status and Eslicarbazepine Patent Landscape

US Patent 10,675,287 protects a narrow method of using eslicarbazepine acetate, the active ingredient in Aptiom, at approximately 1,200 mg once daily for human patients with partial-onset seizures. Its strongest commercial coverage is the branded regimen of oral 1,200-mg once-daily therapy, particularly adjunctive treatment of refractory patients. The patent does not broadly claim eslicarbazepine acetate, all doses, all dosage forms, or the manufacture of the active ingredient.

The claims are method-of-treatment claims. Their practical value depends on whether a generic label, prescribing information, promotional materials, or actual conduct encourages or requires the patented 1,200-mg regimen.

What does US Patent 10,675,287 cover?

The patent covers administering approximately 1,200 mg of eslicarbazepine acetate once daily to a human patient with partial-onset seizures. Independent claim 1 is the principal broad claim.

Claim group	Subject matter	Commercial significance
Claims 1-7	Once-daily approximately 1,200 mg treatment of partial-onset seizures	Covers the core branded dose and indication
Claims 8-21	Once-daily approximately 1,200 mg adjunctive therapy for refractory patients	Targets patients inadequately controlled by another antiepileptic drug
Claims 10-18	Adjunctive use with specified antiepileptic drugs	Narrows coverage to named concomitant therapies
Claims 19	No significant reduction in serum concentration of the other antiepileptic drug	Pharmacokinetic limitation that may be difficult to prove
Claims 20-21	Tablet or oral suspension; oral administration	Covers ordinary commercial delivery routes
Claims 22-23	Initial approximately 400-mg dose, followed by escalation to approximately 1,200 mg	Mirrors the labeled titration strategy

The patent does not claim:

Eslicarbazepine acetate as a chemical compound.
Every once-daily dose.
Doses of 400 mg or 800 mg standing alone.
Twice-daily administration.
Intravenous or nonoral administration.
All epilepsy indications.
Monotherapy at doses other than approximately 1,200 mg.
A particular tablet composition, excipient system, polymorph, manufacturing process, or dissolution profile.

The scope is therefore commercially important but technically narrow.

How should claim 1 of US 10,675,287 be construed?

Claim 1 requires proof of each of the following elements:

A method of treating a patient.
Partial-onset seizures.
Administration to a human.
Approximately 1,200 mg of eslicarbazepine acetate.
Once-daily administration.

The claim does not expressly require adjunctive therapy, refractory disease, oral administration, tablets, a specific treatment duration, or a particular seizure-reduction result. Those limitations appear in dependent claims.

The phrase “about 1200 mg” creates a claim-construction issue. Courts generally interpret “about” according to the intrinsic evidence, including the specification, examples, pharmacokinetic data, regulatory labeling, and prosecution history. A generic product administered at 1,200 mg per day would present a direct infringement risk. A materially different dose could create a noninfringement argument, but the boundary cannot be determined solely from the claim language.

The once-daily limitation is central. A regimen that delivers the same total daily amount in divided doses does not literally satisfy the once-daily requirement. It could still raise a doctrine-of-equivalents issue, although the strength of that argument would depend on the prosecution history and whether the once-daily distinction was used to obtain allowance.

What do claims 8 through 23 add?

Claims 8 through 23 create narrower fallback positions.

Claim 8 requires refractory partial-onset seizures in a human patient experiencing at least four partial-onset seizures per month despite treatment with at least one other antiepileptic drug. This limitation narrows the patient population but may track a substantial portion of the adjunctive-treatment population used in clinical development.

Claim 9 requires adjunctive therapy. Claims 10 through 18 identify specific background drugs:

Phenytoin
Valproate
Primidone
Phenobarbital
Lamotrigine
Gabapentin
Topiramate
Clonazepam
Combinations of those drugs

Claims 11 through 18 separately claim each listed drug. These claims may be useful if a generic label expressly recommends adjunctive use with one or more named antiepileptic drugs.

Claim 19 requires that the serum concentration of the concomitant antiepileptic drug is not significantly decreased. This is a pharmacokinetic limitation. It may be difficult for a patent owner to prove through ordinary prescription records because infringement may depend on patient-specific serum measurements and the meaning of “significantly.”

Claims 22 and 23 cover initiation at approximately 400 mg once daily followed by escalation to approximately 1,200 mg. These claims are closely aligned with the FDA-approved Aptiom titration framework. The FDA label identifies 400 mg once daily as an initial dose and 800 mg once daily as the recommended dosage for many patients, with increases based on response and tolerability. [2]

What is the FDA regulatory status of the patented regimen?

Aptiom, marketed by Sunovion Pharmaceuticals, is approved by the FDA for the treatment of partial-onset seizures in adults. Eslicarbazepine acetate is administered orally and converted principally to eslicarbazepine, the pharmacologically active metabolite. [2]

The FDA labeling identifies once-daily administration and includes 1,200 mg as a clinically relevant dose. The label also describes dose initiation and titration. That overlap increases the commercial significance of claims 1 and 22 because a generic applicant seeking approval for the same indication and dosage instructions may face a method-of-use patent issue.

Regulatory overlap does not itself establish patent infringement. Patent analysis requires comparison of the approved labeling, proposed generic label, patent claims, and any applicable use codes.

What is the Orange Book status of US Patent 10,675,287?

The Orange Book is the controlling FDA source for listed patents and patent-use codes associated with an approved drug product. A patent’s presence in the Orange Book can trigger a Paragraph IV certification requirement for an ANDA applicant, but Orange Book listing does not establish validity or enforceability. [3]

For a method-of-use patent such as US 10,675,287, the relevant issue is the use code. A use code that covers treatment of partial-onset seizures with approximately 1,200 mg once daily could create a substantial ANDA certification obstacle. A narrowly drafted use code may permit a “section viii” carve-out if the generic label omits the patented use. [4]

The supplied claim text alone does not establish:

Whether US 10,675,287 is currently listed for Aptiom.
The applicable Orange Book use code.
Whether the listing has been delisted or withdrawn.
Whether FDA has accepted a Paragraph IV certification against it.
Whether a generic applicant has successfully carved out the patented use.

Those facts must be taken from the current electronic Orange Book and FDA patent-listing records rather than inferred from the patent claims.

When does US Patent 10,675,287 lose exclusivity?

The patent does not expire 20 years after its 2020 issue date. US patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory effects. [5]

Public patent records identify US 10,675,287 as a later-issued patent directed to eslicarbazepine acetate treatment methods. The nominal expiration is expected in the mid-2030s rather than in 2040. The legally operative expiration date must be taken from the USPTO patent-term calculation and any Orange Book listing.

The patent’s term is separate from FDA regulatory exclusivity. FDA exclusivity for the original Aptiom approval is not equivalent to the patent term and does not extend automatically because the patent remains in force. [3]

What patent claims protect Aptiom beyond US 10,675,287?

Aptiom’s broader patent estate may include different categories of protection, depending on the patent and listing status.

Compound and active-ingredient patents

Earlier patents may cover eslicarbazepine acetate or related chemical compounds. These patents generally present the greatest barrier to early generic entry because they can apply regardless of dose, indication, or formulation. Their expiration dates must be evaluated separately from the 10,675,287 method claims.

Formulation patents

Formulation patents may cover:

Immediate-release tablets.
Specific excipients.
Tablet hardness or dissolution.
Stability characteristics.
Particle size or solid-state properties.
Oral suspension formulations.

US 10,675,287 is not a formulation patent. Claims 2 and 20 identify tablets or oral suspensions only as dosage forms used in the treatment method. They do not claim the composition of a tablet or suspension.

Method-of-use patents

US 10,675,287 is principally a dosing and treatment patent. The patent’s commercial center is the 1,200-mg once-daily regimen. Claims 8 through 19 add refractory disease, adjunctive therapy, background antiepileptic drugs, and pharmacokinetic outcomes.

Manufacturing patents

Manufacturing patents may cover synthesis, purification, crystallization, solvent selection, or process controls for eslicarbazepine acetate. These rights can affect API sourcing even when a finished-dose generic avoids a formulation patent. They do not appear in the supplied claim set.

How strong is the patent estate for US Patent 10,675,287?

The patent has meaningful commercial relevance but several attack points.

Strengths

Claim 1 maps directly onto the 1,200-mg once-daily regimen.
The regimen is consistent with the clinical and regulatory use of Aptiom.
The claims cover the ordinary oral route and commercially practical tablets.
Claims 8 and 9 target refractory and adjunctive patients, the core use population for many epilepsy therapies.
Claims 22 and 23 capture a 400-mg initiation followed by escalation to 1,200 mg.

Vulnerabilities

The claims are method claims rather than product claims.
“About 1200 mg” may produce a boundary dispute.
A generic applicant may seek a label that omits the patented 1,200-mg use.
Actual infringement may depend on physician prescribing and patient administration.
The pharmacokinetic limitations in claims 4, 6, 7, and 19 may be vulnerable to enablement, written-description, indefiniteness, or proof-of-infringement arguments.
Prior art may challenge the obviousness of once-daily dosing, dose escalation, and use in refractory partial-onset seizures.
The patent may face double-patenting or terminal-disclaimer issues if it is related to earlier eslicarbazepine patents.

Claims 1 and 8 are the commercially important independent claims. Claims 2-7 and 20-23 provide narrower positions but may be less valuable if a generic product label omits the corresponding details.

What Paragraph IV challenges could affect Aptiom?

An ANDA applicant can make a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed. The filing may trigger patent litigation under the Hatch-Waxman Act. A timely infringement action can produce a 30-month stay of FDA approval, subject to statutory exceptions and court developments. [4]

For US 10,675,287, likely challenge theories include:

Noninfringement through a label that omits 1,200 mg once-daily dosing.
Noninfringement based on a different dosing schedule.
Invalidity based on obviousness over earlier eslicarbazepine clinical or pharmacokinetic disclosures.
Lack of written description for the claimed pharmacokinetic ranges.
Indefiniteness of “about” or “not significantly decreased.”
Lack of enablement across the full scope of the claimed patient population.
Improper claim differentiation or prosecution-history estoppel affecting the doctrine of equivalents.

The actual risk depends heavily on the proposed generic label and the patent’s prosecution history. A product can avoid literal infringement while still being commercially constrained if physicians routinely prescribe the patented dose.

Which companies are challenging Aptiom exclusivity?

Generic competition to Aptiom can arise through ANDA applicants, authorized-generic arrangements, licensing, or acquisition of an existing generic filing. Company-specific conclusions require current FDA ANDA records, Paragraph IV notices, and court dockets.

A reliable competitive review should identify:

Evidence source	What it establishes
FDA Orange Book	Listed patents, use codes, and regulatory certifications
FDA Paragraph IV litigation database or ANDA records	Regulatory challenge and filing status
PACER and district-court dockets	Complaint, injunction, settlement, and judgment status
PTAB records	Inter partes review or post-grant proceedings
SEC filings	Licensing, settlement, launch-risk, and revenue disclosures
FDA Drugs@FDA	Approved labeling and regulatory history

The existence of an ANDA does not establish that a generic can launch. Patent litigation, settlement restrictions, regulatory review, manufacturing readiness, and pediatric or other exclusivity periods can change the launch date.

What generic launch scenarios exist for eslicarbazepine acetate?

Scenario 1: Full-label generic launch after patent expiry

A generic applicant retains the 1,200-mg once-daily regimen and launches after the relevant patent or regulatory barriers expire. This creates the highest substitution potential and the greatest branded revenue exposure.

Scenario 2: Section viii carve-out

The applicant removes the patented use or dose from its label. A carve-out may reduce direct inducement risk but can limit physician substitution, particularly when the omitted regimen is a standard dose. FDA approval of the remaining indications does not resolve all patent-risk questions.

Scenario 3: Paragraph IV litigation and delayed launch

The applicant challenges the patent, but litigation delays approval or launch. The outcome depends on validity, infringement, Orange Book timing, settlement terms, and any court-imposed injunction.

Scenario 4: At-risk launch

A generic launches before final resolution. The applicant may face damages, an injunction, and loss of market access if the patent survives and is infringed. This is a high-risk strategy for a method patent when the label recommends the patented regimen.

How does US 10,675,287 compare with a compound patent?

A compound patent generally has broader infringement coverage because it can reach the active ingredient in any dosage form or indication. US 10,675,287 is narrower because it requires a specific clinical use and dosing regimen.

Issue	US 10,675,287	Compound patent
Right type	Method of treatment	Product or composition
Dose limitation	Approximately 1,200 mg	Usually none
Indication limitation	Partial-onset seizures	Usually none
Design-around potential	Relatively high	Relatively low
Label-carve-out potential	High	Limited
Proof of infringement	Requires treatment-related conduct	Product manufacture, sale, or use
Commercial leverage	Strong for labeled regimen	Strong across product lifecycle

The patent is most valuable if 1,200 mg once daily is the commercially dominant regimen and if generic labels cannot practically omit it.

What is the likely revenue exposure from this patent?

US 10,675,287 creates exposure concentrated in the later-life-cycle Aptiom market. It does not by itself determine the entire product’s loss of exclusivity because other patents, regulatory exclusivity, settlements, and generic strategies may control entry.

Revenue sensitivity depends on:

The share of patients receiving 1,200 mg once daily.
Whether generic labels include or omit that dose.
The number of approved generic suppliers.
Therapeutic substitution by other antiseizure medicines.
Payer conversion rates.
The enforceability of any broader compound or formulation patents.
Whether a settlement provides a licensed entry date.

A method patent can delay full substitution while permitting limited generic sales. It is therefore less predictable than a composition patent for forecasting branded erosion.

Key Takeaways

US 10,675,287 is a method-of-use patent centered on approximately 1,200 mg of eslicarbazepine acetate administered once daily.
Claim 1 covers human treatment of partial-onset seizures without requiring refractory disease or adjunctive therapy.
Claim 8 narrows protection to refractory patients with at least four partial-onset seizures per month despite another antiepileptic drug.
Claims 22 and 23 cover initiation at approximately 400 mg followed by escalation to approximately 1,200 mg.
The patent does not claim eslicarbazepine acetate itself, a tablet composition, a manufacturing process, or every dose.
The principal generic strategies are Paragraph IV invalidity or noninfringement challenges and section viii label carve-outs.
“About 1200 mg,” “steady-state,” “up to,” and “not significantly decreased” create claim-construction and proof issues.
The operative expiration date requires review of USPTO term data, terminal disclaimers, patent-term adjustment, and any Orange Book record.
The patent’s commercial strength depends on whether a generic label recommends the patented regimen and whether the broader Aptiom estate contains earlier compound or formulation rights.

FAQs About US Patent 10,675,287 and Eslicarbazepine

Is US Patent 10,675,287 a formulation patent?

No. It is principally a method-of-treatment patent. Its tablet and oral-suspension limitations describe dosage forms used in the claimed treatment rather than the formulation composition itself.

Does a generic eslicarbazepine product infringe the patent automatically?

No. Infringement depends on the dose, frequency, indication, labeling, and conduct associated with administration. A generic product sold for a noninfringing use may avoid direct infringement, although inducement issues can remain.

Does the patent cover 800 mg Aptiom once daily?

The supplied claims do not expressly cover an 800-mg once-daily regimen. The independent claims require approximately 1,200 mg once daily.

Can an ANDA applicant omit the 1,200-mg dose?

Potentially, through a section viii carve-out or other label strategy, depending on the Orange Book use code and FDA requirements. Omitting the dose may reduce infringement risk but can also limit the product’s clinical and commercial utility.

Is biosimilar litigation relevant to eslicarbazepine acetate?

No. Eslicarbazepine acetate is a small-molecule drug, so the relevant pathway is an ANDA for a generic drug, not a biosimilar application under the biologics framework.

References

United States Patent and Trademark Office. (2020). U.S. Patent No. 10,675,287, methods of treating epilepsy.
U.S. Food and Drug Administration. (2023). Aptiom (eslicarbazepine acetate) prescribing information. Sunovion Pharmaceuticals Inc.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
United States Congress. (1994). Uruguay Round Agreements Act, 35 U.S.C. § 154.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055939	⤷ Start Trial
Australia	2005331690	⤷ Start Trial
Brazil	PI0520258	⤷ Start Trial
Canada	2607427	⤷ Start Trial
Mexico	2007013882	⤷ Start Trial
Mexico	366496	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,675,287

Summary for Patent: 10,675,287